Wall Street Hits New Highs as U.S.-Iran Ceasefire Talks Boost Market Sentiment 
ECB’s Philip Lane Warns Middle East Conflict Could Keep Inflation Elevated 
Dollar Gains Slightly as U.S.-Iran Tensions Keep Forex Markets on Edge 
US Imposes Fresh Iran Oil Sanctions Despite Progress on Ceasefire Talks 
SpaceX IPO Could Become Largest in History with $1.8 Trillion Valuation Target 
Nikkei Hits Record High as AI Chip Stocks Power Japan Market Rally 
S&P 500 Hits Record High as Tech Rally Slows Amid Iran Peace Uncertainty 
Asian Currencies Steady as U.S.-Iran Ceasefire Extension Hopes Weigh on Dollar 
Snowflake Stock Soars 30% After Q1 Earnings Beat and Major AWS AI Partnership 
Synopsys Q2 FY2026 Earnings Beat Driven by AI and Semiconductor Demand 
SK Hynix Joins $1 Trillion Club as AI Chip Demand Fuels Stock Surge 
Samsung Union Dispute Escalates Over Semiconductor Bonus Vote 
US Dollar Slips as Markets Weigh Potential US-Iran Peace Deal and Oil Price Outlook 
New World Screwworm Found Near U.S. Border Raises Threat to Cattle Industry and Beef Prices 
Elon Musk Explores Possible Tesla-SpaceX Merger Amid Growing AI Investments 
Gold Prices Hold Near Record Levels as Inflation Concerns Offset Middle East Ceasefire Hopes 
Tokyo Inflation Cools in May, Supporting BOJ’s Cautious Rate Hike Path 
Merck & Co., Inc. was first revealed to be in the last phase of talks to acquire Prometheus Biosciences Inc., a California-based biotech company. Now, the deal was already confirmed by the company.
Reuters previously reported that sources said the acquisition could be announced on Sunday, April 16. At that time, they were cautious about sharing any other details because there was still a possibility for the talks to fall apart.
But indeed, the deal pushed through, and Merck & Co. has officially acquired Prometheus Biosciences, which specializes in the development and production of therapeutic products for the treatment of immune-mediated diseases. The company’s market capitalization was said to be $5.42 billion at Friday’s closing.
In any case, Merck & Co. was said to be hunting for deals to shield the company from eventual revenue loss because its Keytruda cancer immunotherapy patents are set to expire at the end of the decade. It has also released its 2023 earnings estimates that showed a huge decline in sales of its COVID-19 antiviral treatment.
“At Merck, we are committed to delivering on our purpose to save and improve lives and continue to identify and secure opportunities where compelling science and value creation align,” Merck & Co. chairman and chief executive officer, Robert M. Davis, said in a press release. “The agreement with Prometheus will accelerate our growing presence in immunology where there remains a substantial unmet patient need.”
He added that its acquisition of Prometheus Biosciences “adds diversity to our overall portfolio and is an important building block as we strengthen the sustainable innovation engine that will drive our growth well into the next decade.”
Mark McKenna, the chairman and CEO of Prometheus Biosciences, also commented, “Prometheus was established to revolutionize the treatment of immune-mediated diseases through the application of a powerful precision medicine approach, and this agreement with Merck, a leader in biopharmaceutical research and development, allows Prometheus to maximize the potential for PRA023 while continuing to apply our technology and expertise to fuel further discoveries to address the needs of patients with immune disorders.”
